SEC Settles Insider Trading Suit Over Pharma Deal

By Martin Bricketto

Law360, New York (September 02, 2010, 6:41 PM ET) -- A former hedge fund manager and an executive with a New Jersey-based pharmaceutical company, both facing insider trading charges tied to AstraZeneca’s acquisition of MedImmune Inc. in 2007, have agreed to settle a U.S. Securities and Exchange Commission case against them.

Stephen R. Goldfield, the hedge fund manager, was able to rack up nearly $14 million in illegal profits, thanks to nonpublic information funneled to him by longtime friend and business executive James W. Self Jr., the SEC alleged in a complaint filed Wednesday in the...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles

Sections

Law Firms Mentioned

Government Agencies Mentioned